Similarly, tumor mutational burden (TMB) has emerged as a promising biomarker, with high-TMB tumors demonstrating enriched neoantigen landscapes and potentially greater responsiveness to PD-1/PD-L1 blockade [60]. This evidence concerns the gene CD274 and neoplasm.